Billion-Dollar Molecules: Etavopivat, an Allosteric PKR Kinase Activator for Sickle Cell Disease
Abstract. Novo Nordisk has acquired Forma Therapeutics for $1.1B for its primary investigational drug, etavopivat. Etavopivat, a past Molecule of the Month, is an oral, once-daily allosteric activator of pyruvate kinase-R (PKR), which is currently being tested in Phase II/III clinical trials for the treatment of sickle cell disease and other hemoglobinopathies. In this article, we cover:
- the mechanism of action of the drug
- the clinical context of the acquired portfolio
- the details of the deal
request a trial
You don’t have time to read everything, but you can’t afford to fall behind.
Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.
Get ahead now by requesting a trial.